Abiraterone acetate: a hat trick of clinical benefits
نویسندگان
چکیده
منابع مشابه
Treatment as prevention--a double hat-trick.
208 www.thelancet.com Vol 378 July 16, 2011 4 Family Health International. FHI statement on the FEM-PrEP HIV prevention study. http://minilicious.wordpress.com/2011/04/18/fh i-statement-onthe-fem-prep-hiv-prevention-study/ (accessed June 28, 2011). 5 Abdool Karim SS, Kashuba A, Werner L, Abdool Karim Q. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implicat...
متن کاملVisual Neuroscience: A Hat-Trick for Modularity
A new study using transcranial magnetic stimulation of the brain shows that each of three neighboring areas of visual cortex plays a specific and causal role in perceiving faces, bodies and other kinds of objects.
متن کاملAbiraterone Acetate Withdrawal Syndrome: Does It Exist?
In 2011 abiraterone acetate (AA) was approved for the treatment of castrate-resistant metastatic prostate cancer patients who have failed docetaxel chemotherapy. We report the case of a patient who experienced a confirmed PSA decrease of ≤50% after stopping AA, mimicking an antiandrogen withdrawal syndrome.
متن کاملU.S. FDA Approval Summary: Abiraterone Acetate
1 CCR Perspectives in Drug Approval Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary Paul G. Kluetz, Yang-Min Ning, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Debasis Ghosh, Robeena Aziz, Todd Palmby, Elimika Pfuma, Jeanne Fourie Zirkelbach, Nitin Mehrot...
متن کاملClinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
BACKGROUND Abiraterone acetate and enzalutamide both improve outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing for these agents and whether cross-resistance occurs is unknown. METHODS Multicentre review of patients with mCRPC treated with abiraterone acetate and prednisone after progressing on enzalutamide. Primary objective was to determine...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Oncology
سال: 2012
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70460-6